A股異動 | 新綸新材漲5% 擬2.7億元出售光明產業園 聚焦新材料業務
格隆匯12月8日丨新綸新材(002341.SZ)現漲5.81%,報6.19元,總市值71億元。新綸新材12月7日發佈公吿,公司擬向與信太科技(集團)股份有限公司出售位於深圳市寶安區(光明新區)公明辦事處塘明公路南側的新綸科技產業園(簡稱“光明產業園”),交易價格2.7億元。初步核算,此次交易將為公司帶來利潤約0.54億元。公吿稱,為聚焦新材料業務,進一步提高資產利用效率並優化資產結構,公司積極剝離非材料類業務並處置非核心資產。本次交易有助於緩解公司短期資金壓力,為集中資源,聚焦核心業務發展帶來積極影響。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.